FDA approves new indication for AstraZeneca’s heart disease drug Brilinta
The regulator has approved the company’s heart disease drug Brilinta based on positive data from the phase III THEMIS study. According to the company, the study demonstrated a
VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership